CI-867, a new semisynthetic penicillin, has exhibited broad-spectrum activity in vitro against gram-positive cocci, except penicillin G-resistant Staphylococcus aureus, and against gram-negative bacilli. It was especially active against Pseudomonas aeruginosa and as active as mezlocillin and piperacillin against Klebsiella pneumoniae. CI-867 was bactericidal against most organisms. Its activity was greatly reduced when the inoculum was increased from 105 to 107 organisms per ml.
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The past decade has witnessed the introduction of many new derivatives of penicillins with structural modifications which have increased their spectrum of activity (1, 3, 4) . CI-867, C32H35N501S2Na, (Fig. 1) , a new semisynthetic penicillin prepared from amoxicilhin, is the most recent of these derivatives (7, 10) . This report presents the results of in vitro studies with this drug which indicate its broad spectrum of activity and its superior activity against Pseudomonas aeruginosa in comparison studies with carbenicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, and ampicillin.
MATERIALS AND METHODS
A total of 631 ,tg/ml inhibited all isolates of E. coli, P. aeruginosa, and K. pneumoniae, respectively, using an inoculum of 105 cells per ml, none of these isolates was inhibited by 200 ,ug of CI-867 per ml using an inoculum of 107 cells per ml.
The activity of CI-867 in comparison with those of carbenicillin, ticarcillin, mezlocillin, ANTIMICROB. AGENTS CHEMOTHER.
azlocillin, piperacillin, and ampicillin is shown in Table 2 . CI-867 was the most active antibiotic against isolates of P. aeruginosa. It was twofold more active than piperacillin, the next most active antibiotic, and fourfold more active than azlocillin against 50% of these isolates. CI-867 was slightly less active than mezlocillin, piperacillin, or ticarcillin against isolates of E. coli, although all antibiotics inhibited 75% at achievable concentrations. CI-867 was as active as mezlocillin and piperacillin against isolates of K. CI-867 was not active against strains which were multiply resistant (minimal inhibitory concentration, >200 ,ug/ml), although it is not known whether these are beta-lactamase-producing strains. Therefore, the method of resistance is uncertain. It should be noted that isolates from our patient population are generally more resistant to multiple antibiotics, possibly as a result of extensive use of both commerically available and investigational antimicrobial drugs Inoculum size had a major effect on the activity of CI-867. It was inactive against all isolates of E. coli, K. pneumoniae, and P. aeruginosa when an inoculum of 107 cells per ml was used.
This effect of inoculum variation has been reported in studies of other penicillins, including carbenicillin, azlocillin, and mezlocillin (4, 13, 14) . One suggestion is that the larger inoculum contains a greater number of inherently resistant cells. Another suggestion is the loss of activity of CI-867 due to instability to beta-lactamase. Studies of beta-lactamase production in our group of isolates and studies of the stability of CI-867 to various beta-lactamases would be necessary to confirm this possibility but were not within the scope of this study.
The activity of CI-867 was not affected by the type of medium or the pH in tests on MuellerHinton broth. The first of these variables affects the activity of BLP-1654 and pirbenicillin (5, 6) , and the second affects the activity of azlocillin and mezlocillin (4, 14) .
CI-867 is active against those organisms that most frequently infect the compromised host, P. aeruginosa, K. pneumoniae, and E. coli, but is not active against penicillin G-resistant S. aureus (9) .
In other studies, Cardenas et al. found that CI-867 has a spectrum of antibacterial activity greater than that of ticarcillin and comparable to that of piperacillin (7) . In acute mouse protection tests, Heifetz and Sesnie found CI-867 to be markedly more effective than ticarcillin against P. aeruginosa and K. pneumoniae and more than twice as effective as piperacillin against the fonner (10) .
The spectrum of activity and potency of CI-867 are such that it is not likely to be used as a single drug for treatment of presumptive infection. It might be useful in combination with a cephalosporin or an aminoglycoside. Special in vivo and pharmacological studies are needed to evaluate this possible use.
